Information Provided By: 
Fly News Breaks for April 10, 2018
SPPI
Apr 10, 2018 | 11:29 EDT
After Spectrum reported that MD Anderson's Phase 2 study of poziotinib in patients with advanced nonsmall cell lung cancer with EGFR exon 20 mutations has fully enrolled its initial 30- patient cohort and updated on the initial 11 patients, B. Riley FBR analyst David Buck said he expects one more FDA meeting before a likely filing in 2018. He reiterates a Buy rating and $26 price target on Spectrum shares.
News For SPPI From the Last 2 Days
There are no results for your query SPPI
